Lan Shi

619 total citations
27 papers, 463 citations indexed

About

Lan Shi is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Oncology. According to data from OpenAlex, Lan Shi has authored 27 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Oncology. Recurrent topics in Lan Shi's work include Thyroid Cancer Diagnosis and Treatment (9 papers), Histone Deacetylase Inhibitors Research (4 papers) and Cancer Cells and Metastasis (3 papers). Lan Shi is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (9 papers), Histone Deacetylase Inhibitors Research (4 papers) and Cancer Cells and Metastasis (3 papers). Lan Shi collaborates with scholars based in China, United States and Japan. Lan Shi's co-authors include Chunping Liu, Tao Huang, Jie Ming, Xiu Nie, Xia Xu, Qunzi Zhao, Peixian Zhang, Dong Yang, Hongjiu Dai and Bin Sun and has published in prestigious journals such as Journal of Biological Chemistry, Medicine and Ecotoxicology and Environmental Safety.

In The Last Decade

Lan Shi

25 papers receiving 458 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lan Shi China 11 221 156 145 118 86 27 463
Betsy Morrow United States 11 54 0.2× 180 1.2× 122 0.8× 37 0.3× 56 0.7× 18 497
Manuela Lacerda Portugal 11 39 0.2× 149 1.0× 170 1.2× 58 0.5× 36 0.4× 14 398
Carla Pecchioni Italy 10 105 0.5× 159 1.0× 107 0.7× 36 0.3× 35 0.4× 12 384
Ralf Jesenofsky Germany 12 25 0.1× 258 1.7× 105 0.7× 143 1.2× 95 1.1× 21 452
Jennifer McDevitt United States 9 38 0.2× 207 1.3× 126 0.9× 24 0.2× 105 1.2× 22 338
E T Verghese United Kingdom 6 37 0.2× 110 0.7× 186 1.3× 60 0.5× 20 0.2× 6 429
Sonja Kleffel United States 9 39 0.2× 151 1.0× 152 1.0× 62 0.5× 99 1.2× 10 360
Anja Schultz Germany 13 117 0.5× 84 0.5× 54 0.4× 75 0.6× 86 1.0× 23 588
Ruiping Zhai China 13 27 0.1× 169 1.1× 146 1.0× 103 0.9× 70 0.8× 28 468
Kagenori Ito Japan 10 35 0.2× 76 0.5× 378 2.6× 63 0.5× 45 0.5× 24 524

Countries citing papers authored by Lan Shi

Since Specialization
Citations

This map shows the geographic impact of Lan Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lan Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lan Shi more than expected).

Fields of papers citing papers by Lan Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lan Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lan Shi. The network helps show where Lan Shi may publish in the future.

Co-authorship network of co-authors of Lan Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Lan Shi. A scholar is included among the top collaborators of Lan Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lan Shi. Lan Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Gan, Xinfeng Yao, Yuchen Hou, et al.. (2025). Metabolomic and transcriptomic profiling of HNSCC identifies AMIGO2 as a therapeutic target modulating tumor microenvironment. npj Precision Oncology. 9(1). 358–358.
2.
Wang, Min, et al.. (2025). Phosphogypsum leachate exacerbates histological damage, oxidative stress, apoptosis in the liver, and genotoxicity of heat-stressed zebrafish (Danio rerio). Ecotoxicology and Environmental Safety. 303. 118904–118904. 1 indexed citations
3.
Zhang, Shanshan, Gang Wu, Lan Shi, et al.. (2025). ARID1A deficiency promotes malignant proliferation of hepatocellular carcinoma by activating HDAC7/ENO1 signaling pathway. Hepatology Communications. 9(7). 1 indexed citations
4.
Shi, Lan, et al.. (2024). CDCA5 accelerates progression of breast cancer by promoting the binding of E2F1 and FOXM1. Journal of Translational Medicine. 22(1). 639–639. 5 indexed citations
5.
Shi, Lan, Shanshan Zhang, Gan Liu, et al.. (2024). Toxin protein LukS-PV targeting complement receptor C5aR1 inhibits cell proliferation in hepatocellular carcinoma via the HDAC7–Wnt/β-catenin axis. Journal of Biological Chemistry. 301(2). 108148–108148. 2 indexed citations
6.
Shi, Lan, et al.. (2022). LukS-PV inhibits the proliferation of hepatocellular carcinoma cells by maintaining FOXO3 stability via the PI3K/AKT signaling pathway. Cellular Signalling. 95. 110357–110357. 2 indexed citations
7.
Shi, Lan, et al.. (2022). LukS-PV inhibits hepatocellular carcinoma cells migration by downregulating HDAC6 expression. BMC Cancer. 22(1). 630–630. 7 indexed citations
8.
Xu, Liang, Lan Shi, Shan Shan Zhang, et al.. (2021). LukS-PV Induces Apoptosis via the SET8-H4K20me1-PIK3CB Axis in Human Acute Myeloid Leukemia Cells. Frontiers in Oncology. 11. 718791–718791. 8 indexed citations
9.
10.
Zhang, Peixian, et al.. (2020). <p>LncRNA CRNDE and lncRNA SNHG7 are Promising Biomarkers for Prognosis in Synchronous Colorectal Liver Metastasis Following Hepatectomy</p>. Cancer Management and Research. Volume 12. 1681–1692. 16 indexed citations
11.
Wang, Ziran, Fan Ma, Lan Shi, et al.. (2020). LukS-PV Inhibits Hepatocellular Carcinoma Progression by Downregulating HDAC2 Expression. Molecular Therapy — Oncolytics. 17. 547–561. 12 indexed citations
12.
Yang, Dong, Bin Sun, Hongjiu Dai, et al.. (2019). T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells. Journal for ImmunoTherapy of Cancer. 7(1). 171–171. 80 indexed citations
13.
Ming, Jie, Zeming Liu, Wen Zeng, et al.. (2015). Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer.. PubMed. 8(11). 15155–62. 20 indexed citations
14.
Shi, Lan, Haiping Song, Huiping Zhu, Dapeng Li, & Ning Zhang. (2013). Pattern, predictors and recurrence of cervical lymph node metastases in papillary thyroid cancer. Współczesna Onkologia. 6(6). 504–509. 12 indexed citations
15.
Shi, Lan, et al.. (2013). Treatment for papillary thyroid microcarcinoma. Współczesna Onkologia. 1(1). 20–23. 5 indexed citations
16.
Zhao, Qunzi, Jie Ming, Chunping Liu, et al.. (2012). Multifocality and Total Tumor Diameter Predict Central Neck Lymph Node Metastases in Papillary Thyroid Microcarcinoma. Annals of Surgical Oncology. 20(3). 746–752. 136 indexed citations
17.
Shi, Lan, Huiyu Li, Yanjie Hu, et al.. (2012). Detection of circulating tumor cells and tumor stem cells in patients with breast cancer by using flow cytometry. Tumor Biology. 33(2). 561–569. 35 indexed citations
18.
Ma, Yiming, Mei Zhao, Jialing Zhong, et al.. (2010). Proteomic profiling of proteins associated with lymph node metastasis in colorectal cancer. Journal of Cellular Biochemistry. 110(6). 1512–1519. 46 indexed citations
19.
Liu, Chunping, Huaxiong Pan, Zhi Li, Lan Shi, & Tao Huang. (2009). Histopathological features of invasion of breast invasive ductal carcinoma and safety of breast-conserving surgery. Journal of Huazhong University of Science and Technology [Medical Sciences]. 29(1). 50–52. 6 indexed citations
20.
Shi, Lan, Haiping Song, Chunping Liu, & Tao Huang. (2007). [Effect of PC-cell derived growth factor shRNA on estrogen dependent of estrogen receptor negative breast cancer cell lines].. PubMed. 45(7). 483–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Betsy Morrow Breakdown of academic impact, for papers by Manuela Lacerda Breakdown of academic impact, for papers by Carla Pecchioni Breakdown of academic impact, for papers by Ralf Jesenofsky Breakdown of academic impact, for papers by Jennifer McDevitt Breakdown of academic impact, for papers by E T Verghese Breakdown of academic impact, for papers by Sonja Kleffel Breakdown of academic impact, for papers by Anja Schultz Breakdown of academic impact, for papers by Ruiping Zhai Breakdown of academic impact, for papers by Kagenori Ito
Rankless by CCL
2026